A milestone voluntary licensing agreement has been struck between the Medicines Patent Pool and new partner Novartis for nilotinib to treat chronic myeloid leukemia, marketed by the originator under the Tasigna brand name.
Under the terms of the agreement, selected generic manufacturers will be able to develop, manufacture and supply generic versions of...